Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156405 | 0.85 | PDPK1 (0.44) | PDPK1PIM1TGM2PDGFRBFGFR1 | |
| SCHEMBL3160871 | 0.80 | KMT2A (0.41) | PDPK1PIM1TGM2PDGFRBKDR | |
| SCHEMBL3160648 | 0.79 | PDPK1 (0.44) | PDPK1PIM1TGM2KDRMAPK1 | |
| SCHEMBL3160654 | 0.79 | PDPK1 (0.44) | PDPK1PIM1TGM2KDRMAPK1 | |
| SCHEMBL3148743 | 0.77 | PIM1 (0.46) | PDPK1PIM1TGM2PDGFRBKDR | |
| SCHEMBL7237107 | 0.76 | RET (0.55) | PDPK1TGM2TLK2 | |
| SCHEMBL2572615 | 0.76 | FLT3 (0.42) | PDPK1PIM1TGM2KDR | |
| SCHEMBL2567808 | 0.74 | TGM2 (0.38) | PDPK1TGM2KDR | |
| SCHEMBL3147662 | 0.72 | SMN1; SMN2 (0.43) | MAPK1 | |
| SCHEMBL3156413 | 0.71 | IDO1 (0.42) | PDPK1KDRMAPK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |